[1]
|
陈伟伟, 高润霖, 刘力生. 《中国心血管病报告(2017)》概要[J]. 中国循环杂志, 2018, 33(1): 1-8.
|
[2]
|
国家卫生和计划生育委员会. 中国卫生和计划生育统计年鉴2016 [M]. 北京: 中国协和医科大学出版社, 2016.
|
[3]
|
中华人民共和国卫生部. 中国卫生统计年鉴2009~2012 [M]. 北京: 中国协和医科大学出版社, 2009-2012.
|
[4]
|
Colin, B., Landray, M.J., Christina, R., et al. (2011) The Effects of Lowering LDL Cholesterol with Simvastatin plus Ezetimibe in Patients with Chronic Kidney Disease (Study of Heart and Renal Protection): A Randomised Placebo-Controlled Trial. Lancet, 377, 2181-2192. https://doi.org/10.1016/S0140-6736(11)60739-3
|
[5]
|
Seidah, N.G., Benjannet, S., Wickham, L., et al. (2003) The Secretory Pro-protein Convertase Neural Apoptosis-Regulated Convertase 1 (NARC-1): Liver Regeneration and Neuronal Differentiation. Proceed-ings of the National Academy of Sciences of the United States of America, 100, 928-933. https://doi.org/10.1073/pnas.0335507100
|
[6]
|
Stein, E.A., Mellis, S., Yancopoulos, G.D., et al. (2012) Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. The New England Journal of Medicine, 366, 1108-1118. https://doi.org/10.1056/NEJMoa1105803
|
[7]
|
Koren, M.J., Scot,t R., Kim, J.B., et al. (2012) Efficacy, Safety, and Tolerability of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 as Monotherapy in Patients with Hypercholesterolaemia (MENDEL): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study. Lancet, 380, 1995-2006.
https://doi.org/10.1016/S0140-6736(12)61771-1
|
[8]
|
Giugliano, R.P., Desai, N.R., Kohli, P., et al. (2012) Efficacy, Safety, and Tolerability of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 in Combination with a Statin in Patients with Hypercholesterolaemia (LAPLACE-TIMI 57): A Randomised, Placebo-Controlled, Dose-Ranging, Phase 2 Study. Lancet, 380, 2007-2017.
https://doi.org/10.1016/S0140-6736(12)61770-X
|
[9]
|
Wu, Q., Tang, Z.H., Peng, J., et al. (2014) The Dual Behavior of PCSK9 in the Regulation of Apoptosis Is Crucial in Alzheimer’s Disease Progression (Review). Biomedical Reports, 2, 167-171. https://doi.org/10.3892/br.2013.213
|
[10]
|
Mbikay, M., Sirois, F., Mayne, J., et al. (2010) PCSK9-Deficient Mice Exhibit Impaired Glucose Tolerance and Pancreatic Islet Abnormalities. FEBS Letters, 584, 701-706. https://doi.org/10.1016/j.febslet.2009.12.018
|
[11]
|
GouniBerthold, I. and Berthold, H.K. (2015) Mipomersen and Lomitapide: Two New Drugs for the Treatment of Homozygous Familial Hypercholesterolemia. Atherosclerosis Supplements, 18, 28-34.
https://doi.org/10.1016/j.atherosclerosissup.2015.02.005
|
[12]
|
Cuchel, M. and Rader, D.J. (2013) Microsomal Transfer Protein Inhibition in Humans. Current Opinion in Lipidology, 24, 246-250. https://doi.org/10.1097/MOL.0b013e32836139df
|
[13]
|
Wetterau, J.R., Gregg, R.E., Harrity, T.W., et al. (1998) An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits. Science, 282, 751-754. https://doi.org/10.1126/science.282.5389.751
|
[14]
|
Cuchel, M., Bloedon, L.T., Szapary, P.O., et al. (2007) Inhibition of Micro-somal Triglyceride Transfer Protein in Familial Hypercholesterolemia. The New England Journal of Medicine, 356, 148-156.
https://doi.org/10.1056/NEJMoa061189
|
[15]
|
Samaha, F.F., McKenney, J., Bloedon, L.T., et al. (2008) Inhibition of Microsomal Triglyceride Transfer Protein Alone or with Ezetimibe in Patients with Moderate Hypercholesterolemia. Nature Clinical Practice Car-diovascular Medicine, 5, 497-505. https://doi.org/10.1038/ncpcardio1250
|
[16]
|
Harris, W.S., Miller, M., Tighe, A.P., et al. (2008) Omega-3 Fatty Acids and Coronary Heart Disease Risk: Clinical and Mechanistic Perspectives. Atherosclerosis, 197, 12-24. https://doi.org/10.1016/j.atherosclerosis.2007.11.008
|
[17]
|
Davidson, M.H., Stein, E.A., Bays, H.E., et al. (2007) Efficacy and Tolerability of Adding Prescription Omega-3 Fatty Acids 4 g/d to Simvastatin 40 mg/d in Hypertriglyceridemic Patients: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study. Clinical Therapeutics, 29, 1354-1367. https://doi.org/10.1016/j.clinthera.2007.07.018
|
[18]
|
Ballantyne, C.M., Bays, H.E., Kastelein, J.J., et al. (2012) Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients with Persistent High Triglycerides (from the ANCHOR Study). American Journal of Cardiology, 110, 984-992. https://doi.org/10.1016/j.amjcard.2012.05.031
|
[19]
|
Robins, S.J., Collins, D., Wittes, J.T., et al. (2001) Relation of Gemfibrozil Treatment and Lipid Levels with Major Coronary Events: VA-HIT: A Randomized Controlled Trial. JAMA, 285, 1585-1591.
https://doi.org/10.1001/jama.285.12.1585
|
[20]
|
Barter, P.J. and Kastelein, J.J. (2006) Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease. Journal of the American College of Cardiology, 47, 492-499.
https://doi.org/10.1016/j.jacc.2005.09.042
|
[21]
|
Brown, B.G., Zhao, X.Q., Chait, A., et al. (2001) Simvastatin and Niacin, Anti-oxidant Vitamins, or the Combination for the Prevention of Coronary Disease. The New England Journal of Medicine, 345, 1583-1592.
https://doi.org/10.1056/NEJMoa011090
|
[22]
|
Forrester, J.S. and Shah, P.K. (2006) Emerging Strategies for Increasing High-Density Lipoprotein. American Journal of Cardiology, 98, 1542-1549. https://doi.org/10.1016/j.amjcard.2006.06.059
|
[23]
|
Eyvazian, V.A. and Frishman, W.H. (2017) Evacetrapib: Another CETP In-hibitor for Dyslipidemia with No Clinical Benefit. Cardiology in Review, 25, 43-52. https://doi.org/10.1097/CRD.0000000000000137
|
[24]
|
Brinton, E.A., Kher, U., Shah, S., et al. (2015) Effects of Anacetrapib on Plasma Lipids in Specific Patient Subgroups in the Define (Determining the Efficacy and Tolerability of CETP Inhibition with Anace-trapib) Trial. Journal of Clinical Lipidology, 9, 65-71. https://doi.org/10.1016/j.jacl.2014.10.005
|
[25]
|
Hovingh, G.K., Kastelein, J.J., Van Deventer, S.J., et al. (2015) Cholesterolester Transfer Protein Inhibition by TA-8995 in Patients with Mild Dyslipidemia (TULIP): A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial. The Lancet, 386, 452-460. https://doi.org/10.1016/S0140-6736(15)60158-1
|